Roche’s Vabysmo showcases stronghold across wAMD and DME spaces : GlobalData GlobalData Jun 10, 2024 The data showcases Vabysmo’s efficacy in wet age-related macular degeneration (wAMD) and diabetic macular edema (DME)
New data confirm Roche’s Vabysmo improves vision with fewer treatments for people with neovascular… EP News Bureau Jul 15, 2022 In the Tenaya and Lucerne studies, more than 60 per cent of Vabysmo patients could be treated every four months at two years. This…
FDA approves Roche’s Vabysmo to treat nAMD and DME EP News Bureau Feb 1, 2022 Vabysmo is the only injectable eye medicine approved simultaneously in the US for neovascular Age-related Macular Degeneration…
